

19 January 2018

NSX Announcement

Dual Listed on Frankfurt Stock Exchange

Beroni Group Limited (“Beroni” or the “Company”) (NSX:BTG) is pleased to announce that it has been admitted to the Frankfurt Stock Exchange’s (“FSE”) Open Market Quotation Board (Regulated Unofficial Market). The FSE has assigned ticker code “6B9” to Beroni. No new shares were issued or funds raised under the FSE dual-listing process.

The Company intends to accelerate the review of other business opportunities and use both the NSX and the FSE exchanges as platforms to attract investors and to grow its existing business. Additionally, the Company is looking at partnering with other biomedicine industry leaders by way of research joint ventures and clinical trials for potential new high growth biomedicine products.

For further information please contact:

Mr Jacky Zhang

Executive Chairman

Tel: +86 1851 6931 911

E: 1710426553@qq.com

Mr Peter Wong

Non-Executive Director

Tel: +61 423 727 580

E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group’s currently has four main products: NicoBloc, Fogibloc, Multi Vigorous tablets (Bei Jingli) and Multi lung cleaning tablets (Bei Feiqing). Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries. The Company is open to acquisition opportunities to expand the business and increase its market share.